Related Experiment Video

Updated: Jul 3, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[Management of chronic hepatitis B in treatment-naive patients]

Jae Youn Cheong1

  • 1Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea. jaeyoun620@ajou.ac.kr

The Korean Journal of Gastroenterology = Taehan Sohwagi Hakhoe Chi
|July 8, 2008
PubMed

Insights

Chronic hepatitis B (CHB) management in Korea involves understanding infection phases and approved antiviral therapies. Current guidelines address treatment options, but optimal agent selection, duration, and criteria remain under investigation.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Chronic hepatitis B (CHB) is a significant public health concern in Korea.
  • Understanding the natural history of chronic hepatitis B virus (HBV) infection, divided into four phases (immune tolerance, immune clearance, inactive HBsAg carrier state, and reactivation), is crucial for management.
  • While treatment is not required during immune tolerance and inactive carrier states, patients in immune clearance or reactivation phases are candidates for therapy.

Purpose of the Study:

  • To update treatment recommendations for CHB management in Korea.
  • To incorporate new therapeutic options into clinical practice guidelines.
  • To address uncertainties regarding optimal antiviral therapy, including agent selection, treatment duration, and criteria for initiating, continuing, switching, or stopping therapy.

Main Methods:

  • Review of current therapeutic agents approved for CHB treatment in Korea, including interferon alpha, pegylated interferon alpha, lamivudine, adefovir, entecavir, telbivudine, and clevudine.
  • Update of the 2004 Korean Association for the Study of the Liver guideline on CHB management.
  • Consideration of factors such as efficacy, safety, resistance incidence, and administration methods for antiviral therapy in treatment-naive patients.

Main Results:

  • Several antiviral agents are approved for CHB treatment in Korea.
  • Updated guidelines incorporate new therapeutic options.
  • Key considerations for treatment include efficacy, safety, resistance, and administration route.

Conclusions:

  • The management of CHB requires careful consideration of the patient's disease phase and available treatment options.
  • Ongoing research is needed to determine the most effective antiviral agents, optimal treatment durations, and precise criteria for therapy initiation, continuation, and cessation.
  • Addressing issues of efficacy, safety, resistance, and administration is vital for improving CHB treatment outcomes.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...